← Leaderboards
Paula M Vertino
Emory University
$14,991,018
Attributed
$14,991,018
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $7.7M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,991,018 · 8
By mechanism
R01$7,226,996 · 3
C06$7,160,413 · 1
P30$596,609 · 3
R13$7,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Emory University
Same institution · by research overlap
- William G. Kelly$5,671,631
- Anne Lang Dunlop$11,135,883
- Thomas Spurgeon Wingo$12,227,212
- Anke Huels$3,776,496
- Charles B Nemeroff$22,679,135
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsEpigenetic ProcessMolecularGenesCancer CellChromatinGene ExpressionMethylationGenome-WideCellsProgramsPhenotypePlayTechnologyVariantResponseInsightSourceEnvironmentMediatingComplexFundingGenomeBase
Grant awards (42)
Establishment of the WNY Spatial Biology Resource Center$7,160,413
C06 · FY2025 · OD · contact PI
Relaxed Polymerase Pausing as a Driver of Epigenetic Plasticity and Cancer Cell Invasion$417,469
R01 · FY2025 · CA · contact PI
Relaxed Polymerase Pausing as a Driver of Epigenetic Plasticity and Cancer Cell Invasion$62,640
R01 · FY2025 · CA · contact PI
Genetics, Epigenetics and Metabolism Research Program$37,440
P30 · FY2025 · CA · contact PI
Relaxed Polymerase Pausing as a Driver of Epigenetic Plasticity and Cancer Cell Invasion$396,596
R01 · FY2024 · CA · contact PI
Relaxed Polymerase Pausing as a Driver of Epigenetic Plasticity and Cancer Cell Invasion$56,376
R01 · FY2024 · CA · contact PI
Relaxed Polymerase Pausing as a Driver of Epigenetic Plasticity and Cancer Cell Invasion$409,120
R01 · FY2023 · CA · contact PI
Relaxed Polymerase Pausing as a Driver of Epigenetic Plasticity and Cancer Cell Invasion$62,640
R01 · FY2023 · CA · contact PI
Relaxed Polymerase Pausing as a Driver of Epigenetic Plasticity and Cancer Cell Invasion$413,001
R01 · FY2022 · CA · contact PI
Relaxed Polymerase Pausing as a Driver of Epigenetic Plasticity and Cancer Cell Invasion$428,899
R01 · FY2021 · CA · contact PI
Cancer Genetics and Epigenetics$82,644
P30 · FY2021 · CA · contact PI
Cancer Genetics and Epigenetics$82,644
P30 · FY2020 · CA · contact PI
Cancer Genetics and Epigenetics$82,644
P30 · FY2019 · CA · contact PI
Cancer Genetics and Epigenetics$82,644
P30 · FY2018 · CA · contact PI
Cancer Genetics and Epigenetics$13,365
P30 · FY2018 · CA · contact PI
Cancer Genetics and Epigenetics$4,861
P30 · FY2018 · CA · contact PI
Cancer Genetics and Epigenetics$50,360
P30 · FY2017 · CA · contact PI
Genesis and Consequences of Aberrant DNA Methylation$300,511
R01 · FY2016 · CA · contact PI
Cancer GENETICS AND EPIGENETICS$34,093
P30 · FY2016 · CA · contact PI
Genesis and Consequences of Aberrant DNA Methylation$300,511
R01 · FY2015 · CA · contact PI
Cancer GENETICS AND EPIGENETICS$34,093
P30 · FY2015 · CA · contact PI
Genesis and Consequences of Aberrant DNA Methylation$291,495
R01 · FY2014 · CA · contact PI
Cancer GENETICS AND EPIGENETICS$31,270
P30 · FY2014 · CA · contact PI
Defining Genomic Signatures for Aberrant DNA Methylation in Human Cancers$287,765
R01 · FY2013 · CA · contact PI
Genesis and Consequences of Aberrant DNA Methylation$282,480
R01 · FY2013 · CA · contact PI
Cancer GENETICS AND EPIGENETICS$27,991
P30 · FY2013 · CA · contact PI
Cancer GENETICS AND EPIGENETICS$2,340
P30 · FY2013 · CA · contact PI
Defining Genomic Signatures for Aberrant DNA Methylation in Human Cancers$306,133
R01 · FY2012 · CA · contact PI
Genesis and Consequences of Aberrant DNA Methylation$299,869
R01 · FY2012 · CA · contact PI
Cancer GENETICS AND EPIGENETICS$30,220
P30 · FY2012 · CA · contact PI
Defining Genomic Signatures for Aberrant DNA Methylation in Human Cancers$306,133
R01 · FY2011 · CA · contact PI
Defining Genomic Signatures for Aberrant DNA Methylation in Human Cancers$315,601
R01 · FY2010 · CA · contact PI
2010 FASEB Conference "Biological Methylation:From DNA to Histones and Beyond"$7,000
R13 · FY2010 · CA · contact PI
Defining Genomic Signatures for Aberrant DNA Methylation in Human Cancers$329,351
R01 · FY2009 · CA · contact PI
Genesis and Consequences of Aberrant DNA Methylation$294,732
R01 · FY2008 · CA · contact PI
Genesis and Consequences of Aberrant DNA Methylation$294,732
R01 · FY2007 · CA · contact PI
Genesis and Consequences of Aberrant DNA Methylation$248,385
R01 · FY2006 · CA · contact PI
Genesis and Consequences of Aberrant DNA Methylation$254,363
R01 · FY2005 · CA
Genesis and Consequences of Aberrant DNA Methylation$244,293
R01 · FY2004 · CA
GENESIS AND CONSEQUENCES OF ABERRANT DNA METHYLATION$214,142
R01 · FY2002 · CA
GENESIS AND CONSEQUENCES OF ABERRANT DNA METHYLATION$207,906
R01 · FY2001 · CA
GENESIS AND CONSEQUENCES OF ABERRANT DNA METHYLATION$201,853
R01 · FY2000 · CA